Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. (Nasdaq: LEXX) is a biotechnology company centered on DehydraTECH™, a patented oral drug delivery formulation and processing platform. Company news releases highlight ongoing research and development programs where DehydraTECH is evaluated with active pharmaceutical ingredients such as GLP-1 drugs and cannabidiol (CBD), as well as updates on licensing, partnerships and capital markets activity.
Investors following LEXX news can expect detailed coverage of clinical and preclinical study results, particularly in the GLP-1 sector. Recent announcements describe human pilot studies and a registered Phase 1b study in Australia that compare DehydraTECH-based oral formulations of semaglutide, tirzepatide and liraglutide against existing injectable or oral reference products. These updates often include information on safety, tolerability, adverse events, blood glucose and HbA1c changes, body weight, biodistribution and blood pressure outcomes.
Lexaria’s news flow also includes strategic and business development updates, such as the extension of a Material Transfer Agreement with a pharmaceutical company evaluating DehydraTECH, the engagement of a global life science business development advisory firm, and commentary on how new data sets are being used to guide future R&D plans. In addition, the company regularly reports on financing transactions via registered direct offerings and private placements, describing how proceeds are intended to support research, working capital and general corporate purposes.
For readers tracking LEXX, this news page provides a centralized view of the company’s scientific progress, intellectual property developments, partnership discussions and funding activities related to its DehydraTECH platform.
Lexaria Bioscience has completed dosing for its second human pilot study, GLP-1-H24-2, involving semaglutide. The study compared three 7 mg formulations: Rybelsus® swallowed tablets, DehydraTECH-semaglutide swallowed capsules, and an in-mouth dissolvable DehydraTECH-semaglutide tablet. This investigation aims to determine if DehydraTECH can enhance semaglutide absorption through oral tissues, potentially reducing side effects associated with stomach acid degradation. All blood samples are now being analyzed, with results expected by late August or early September. Lexaria is also optimizing semaglutide formulations in ongoing animal and upcoming 12-week human studies.
Lexaria Bioscience Corp. (NASDAQ:LEXX) has announced the receipt of three new patents, expanding its global patent portfolio to 46.
In the European Union, Lexaria received a patent in its family #6 for transdermal and dermal delivery of lipophilic active agents, valid in ten countries including the UK and Germany, expiring in 2039. In Canada, a new patent in family #18 for enhanced delivery of antiviral agents was granted, expiring in 2041. This patent builds on research showing improved drug delivery rates of 42% to 204% using DehydraTECH. Additionally, Lexaria received a fourth US patent in family #24 for treating epilepsy, expiring in 2044, based on research demonstrating DehydraTECH-CBD’s effectiveness in reducing seizures compared to Epidiolex®.
These patents strengthen Lexaria's intellectual property and support their future business goals.
Lexaria Bioscience has awarded a contract research organization (CRO) to oversee a 12-week chronic human study, GLP-1-H24-4, evaluating DehydraTECH-GLP-1 formulations for weight loss and blood sugar reduction.
The study, the company’s most comprehensive GLP-1 investigation, will involve clinical sites in Australia and comply with Australian regulatory standards. Upon completion, it aims to gain recognition as a Phase 1b study by the U.S. FDA. Study preparations with the CRO include clinical protocol design, regulatory submissions, and data management planning.
Lexaria Bioscience continues progressing its second GLP-1 human pilot study (GLP-1-H24-2), with the second dosing arm now complete for all nine participants. The study, a three-arm crossover investigation, compares three 7 mg semaglutide dose formulations: a positive control Rybelsus® tablet, DehydraTECH-semaglutide swallowed capsules, and an innovative in-mouth dissolvable DehydraTECH-semaglutide oral tablet. This is the first study to investigate if DehydraTECH-enhanced semaglutide can be absorbed systemically via sublingual/buccal tissues, potentially offering better absorption and fewer side effects than swallowed administration. Lexaria plans to complete the final study arm by early July 2024.
Lexaria Bioscience has awarded a contract for its third human pilot study to a contract research organization. This study will evaluate the dual action glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) using a DehydraTECH-processed tirzepatide in an oral capsule format versus the injected tirzepatide (Zepbound® by Eli Lilly). The study aims to determine the absorption, human tolerability, and blood sugar level effects of the oral DehydraTECH-processed tirzepatide. This marks the first study of its kind for Lexaria, potentially paving the way for an FDA-approved oral dosage format of tirzepatide. Manufacturing for the study's test articles is expected to complete within 30 days, pending Independent Review Board approval.
Lexaria Bioscience has announced the receipt of two new US patents in the medical fields of hypertension and epilepsy. The first patent, part of Lexaria's patent family #21, focuses on compositions and methods for treating hypertension using DehydraTECH-processed cannabidiol (CBD). The second patent, part of patent family #24, pertains to treating epilepsy, highlighting DehydraTECH-CBD's efficacy in mitigating epileptic seizures and its superior absorption compared to Epidiolex. Both patents are valid until 2042. Lexaria now holds a total of 43 patents globally, reinforcing its strategic business objectives.
Lexaria Bioscience Corp. (NASDAQ: LEXX) has commenced dosing in a 12-week animal study, WEIGHT-A24-1, to evaluate the effectiveness of DehydraTECH-processed GLP-1 drugs, including semaglutide and liraglutide, in diabetic preconditioned rats. The study aims to determine whether these processed drugs improve brain absorption, weight loss, and blood sugar control, especially when combined with cannabidiol (CBD). The study consists of 12 arms, with initial evaluations focusing on pure and reformulated compositions of semaglutide and liraglutide. Subsequent study arms will explore the best-performing drug combinations and include placebo and positive control groups.
Lexaria Bioscience Corp. has commenced its second GLP-1 human pilot study, comparing different formulations of semaglutide for improved drug delivery. The study aims to test the effectiveness of DehydraTECH technology in enhancing oral absorption rates of GLP-1 drugs. The company has successfully completed the first dosing visit for all nine participants and expects the study to conclude by mid-June.
Lexaria Bioscience Corp. announces a research program with the National Research Council of Canada to evaluate DehydraTECH-GLP-1 drugs. The program will assess the molecular characteristics of semaglutide processed with DehydraTECH and its performance in simulated gastric conditions. The partnership aims to accelerate the integration of DehydraTECH with GLP-1 drugs into the pharmaceutical industry. Testing methods include PAGE, SEC, MALDI MS, and DLS to study the oligomerization potential of DehydraTECH-processed semaglutide. Initial results show increased peak levels of semaglutide in blood with reduced adverse events and improved blood sugar control compared to unprocessed Rybelsus® tablets.
Lexaria Bioscience Corp. (NASDAQ: LEXX) announces a warrant exercise agreement with an investor, resulting in $4.7 million in gross proceeds. The company will issue new warrants at $4.75 per share, extending its operational runway into 2025. The funds will be used for working capital and general corporate purposes.